Researchers presented clinical-trial data today at a conference in Stockholm, showing that it significantly reduces the risk of kidney failure and death for people with type 2 diabetes and chronic kidney disease. Scientists are thrilled with the result, and think that the drug, otherwise known by its generic name, semaglutide, will eventually be proved to help a more general population of people with kidney disease.
Source: Rachel Fairbank for Nature
Speaking of diabetes treatments, semaglutide can’t and won’t stop. The drug, which was originally developed as a diabetes treatment, rose to fame as a weight loss drug and has since been proven to treat a wide array of potential ailments. It can now add kidney disease to its list.
Earlier this week, researchers shared clinical trial data showing that semaglutide significantly reduces the risk of kidney failure and death for people with type 2 diabetes and chronic kidney disease…which, as discussed above, impacts a ton of people globally. The shared data does not come as much of a surprise, as a kidney disease trial was halted early last year after the initial results were so positive that it didn’t make sense to continue the trial. Yet, this is the first look into just how positive those results are:
- 24% less major kidney disease events (including kidney failure) with semaglutide vs. placebo.
- 29% reduction in cardiovascular deaths and major incidents; 20% reduction in overall mortality.
- Significant benefits for patients with type 2 diabetes and chronic kidney disease.
It’s semaglutide’s world; we’re just living in it (thanks to semaglutide). Once again, GLP won.